The first GLP-1 oral pill is now available at pharmacies nationwide. The Wegovy pill was approved by the Food and Drug Administration on December 22. Having an oral version of the medication, which had only been available as an injectable until now,

Furthermore, GLP-1 drugs had a favorable safety profile versus aspirin, particularly with respect to bleeding events, said Colton Frisco Jones, MD, of the University of Texas at San Antonio, during a press briefing prior to the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.

With GLP-1 use rising across the country, major brands are boosting protein, cutting sugar, and reworking formulations and packaging to fit how shoppers are eating today.

If a patient doesn’t respond well to GLP-1s, there are other things to try. But ultimately, the medications just might not work for them.

Some dietary supplements may help naturally boost GLP-1, but more research is needed to better understand their potential benefits. Learn more.

Obese patients with type 2 diabetes are less likely to need a CPAP machine to treat sleep apnea if they’re taking a GLP-1 drug, researchers recently reported in JAMA Network Open. Patients were also less likely to die or require hospitalization when taking GLP-1 drugs,

Novo’s oral Wegovy launch has intensified competition for Eli Lilly heading into 2026. ・Lilly’s outlook hinges on oral drug approvals, data readouts and execution this year. ・Eli Lilly’s share weakness reflects pricing pressure amid the GLP-1 rivalry.

A study by Mass General Brigham, published in the JAMA medical journal, found that discontinuing popular weight loss medications known as GLP-1s could cause complications for pregnant women.

GLP-1 weight loss drugs such as Ozempic and Wegovy have taken the world by storm. But some side effects, from the accepted - 'Ozempic face' and gastrointestinal complaints - to the highly speculated - acute pancreatitis and blindness - have been linked to the drugs.

Benefits of GLP-1 RAs were consistent across age groups and BMI categories, with semaglutide showing significant efficacy. These results were presented during the press briefing ahead of the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

There's a new pill and new ways to pay for the weight-loss drugs known as GLP-1s.

And in a phase III trial win, Foresee Pharmaceuticals said its long-acting gonadotropin-releasing hormone agonist leuprolide mesylate -- already used to treat prostate cancer -- suppressed serum luteinizing hormone concentrations in children with central precocious puberty within 24 weeks.